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EXPERIMENTAL STUDIES 
Idiopathic Atrial Fibrillation in Dogs: Electrophysiologic Determinants 
and Mechanisms of Antiarrhythmic Action of Flecainide 
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Montreal, Quebec, Canada 
Objectives. This study sought to determine the mechanisms of 
idiopathic atrial fibrillation and the atrial antifibrillatory action 
of flecainide in dogs. 
Background. In a small subset of dogs, sustained atrial fibril- 
lation can be readily induced in the absence of vagal tone. The 
electrophysiologic mechanisms underlying this ability to sustain 
atrial fibrillation, and of flecainide action on the arrhythmia, are 
unknown. 
Methods. Six dogs with inducible sustained atrial fibrillation 
were studied before and after flecainide administration and 
compared with a control group of 10 dogs. 
Results. Dogs with atrial fibrillation differed in displaying more 
shortening of the atrial refractory period with increased rate, 
resulting in a significantly shorter refractory period and wave- 
length for reentry at rapid rates, and in increased regional 
dispersion in refractoriness. Activation maps during sustained 
fibrillation showed a mean (+SE) of 6.3 + 0.4 coexistent zones of 
reentry, compatible with short wavelengths, whereas in control 
dogs activation during self-limited atrial fibrillation was better 
organized, and the number of reentrant circuits was smaller. 
Quantitative analysis demonstrated significantly greater inhomo- 
geneity of activation during atrial fibrillation in dogs with atrial 
fibrillation than in control animals. Flecainide terminated 
atrial fibrillation by increasing the duration and homogeneity 
of atrial refractoriness at rapid rates, thereby reducing the 
number of reentry circuits and the heterogeneity of activation. 
Conclusions. The ability of atrial fibrillation to sustain itself 
resulted from enhanced rate-dependent shortening of atrial re- 
fractoriness and increased regional heterogeneity. Flecainide re- 
versed these changes and restored sinus rhythm. These results 
suggest potential mechanisms of idiopathic atrial fibrillation and 
are pertinent to understanding the clinical actions of flecainide. 
(JAm CoU Cardiol 1995;26:277-86) 
Although atrial fibrillation is one of the most common arrhyth- 
mias encountered in clinical practice, the mechanisms and 
determinants of atrial fibrillation remain incompletely under- 
stood. One of the factors limiting our understanding of atrial 
fibrillation is a lack of readily accessible and appropriate 
animal models. Investigators have studied repetitive atrial 
responses and brief episodes of atrial fibrillation induced by 
programmed electrical stimulation i  normal animals (1,2), but 
the self-limited and potentially variable nature of these ar- 
rhythmias make them difficult to study and render the results 
of uncertain relevance to sustained arrhythmias. Cholinergic 
stimulation enhances usceptibility to atrial fibrillation (3-6), 
and we have previously used vagally mediated sustained atrial 
fibrillation extensively as a model to study the mechanisms of
antiarrhythmic drug action (7-9). An important limitation of 
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the cholinergic atrial fibrillation model is that interactions 
between cholinergic and drug effects may occur, making it 
difficult to determine the extent o which observations in this 
model can be applied to the clinical setting. 
We have previously shown (7) that flecainide terminates atrial 
fibrillation in the vagotonic model by causing tachycardia- 
dependent increases in atrial refractoriness and wavelength at the 
rapid rates characteristic ofatrial fibrillation. These observations 
are consistent with previous observations of flecainide's cellular 
effects on superfused atrial preparations from multiple species, 
including dogs and humans (10). The changes in refractoriness 
caused by flecainide were increased in the presence of vagal 
stimulation, raising questions about he relevance of flecainide's 
effects in the vagal model to effects on atrial fibrillation in the 
presence of normal autonomic tone. 
Over a 3-year period, -300 dogs have undergone atrial 
stimulation protocols that included refractory period determi- 
nations and pacing at various basic cycle lengths in our 
laboratory. In six of these dogs, all of whom had bilateral 
cervical vagotomies as part of the experimental preparation, 
sustained atrial fibrillation could readily be induced by criti- 
cally timed atrial extrastimuli or rapid atrial pacing. The 
purpose of the present experiments was to evaluate the 
physiologic substrate of atrial fibrillation and its response to 
flecainide administration in these dogs. Specific objectives 
included the following: 1) to assess atrial electropbysiologic 
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Figure I. Diagram of the electrode arrays. The position of 
each recording electrode is shown by a code containing a
letter (from A to N) and a number (from 1 to 8). Numbers 
without letters indicate the positions of stimulating elec- 
trodes. AVR = atrioventricular ring; IVC (SVC) = inferior 
(superior) vena cava; LAA (RAA) - left (right) atrial 
appendage; PV = pulmonary veins; S = site of stimulation 
used to determine the rate dependence of conduction and 
effective refractory period. 
properties associated with the ability to sustain atrial fibrilla- 
tion; 2) to relate these properties to the mechanisms underly- 
ing the ability to manifest sustained atrial fibrillation; and 3) to 
determine the effects of flecainide on atrial electrophysiology 
and the ability to sustain atrial fibrillation. A concurrent 
control group of l0 dogs was sclccted to compare results in 
dogs with nonvagal atrial fibrillation with more typical dogs in 
whom it is impossible to produce sustained atrial fibrillation in the 
absence of intense vagal nerve stimulation. 
Methods 
Adult mongrel dogs (weight 21 to 31 kg) were anesthetized 
with morphine (2 mg/kg body weight intramuscularly) and 
alpha-chloralose (100 mgjkg intravenously) and ventilated with 
room air supplemented with oxygen. Respiratory. variablcs 
were adjusted to maintain physiologic arterial blood gases 
(arterial oxygen saturation >9(V,'i. pH 7.38 to 7.44). Catheters 
were inserted into the tcft femoral artery and both femoral 
veins and were kept patent with heparinizcd saline solution 
(0.9%). A median sternotomy was performed, and a pericar- 
dial cradle was created. Body temperaturc was kept constant 
with a homeothermic heating blanket. Two bipolar Teflon- 
coated stainless teel electrodes wcre inserted into the right 
atrial appendage for recording and stimulation. A programma- 
ble stimulator (Digital Cardiovascular Instruments) was uscd 
to deliver 4-m8 pulses at twice-threshold current, A demand 
pacemaker (GBM 5880 Demand Pacemaker, Medtronic, Inc.) 
was used to pace the right ventricle when the ventricular rate 
was <90/min. A P23 I D prcssure transducer (Statham Medical 
Instruments), electrophysiologic amplifiers (Bloom Ltd.) and a 
paper recorder (Astromcd MT-95/)()0) were used to record 
standard surface electrocardiographic leads, an atrial electro- 
gram and stimulus artifacts. The vagus nerves were isolated in 
the neck, doubly ligated and divided. Nadolol was adminis- 
tered at an initial dose of 0.5 mg/kg intravenously, followed by 
0.25 mg/kg every 2 h to produce sustained and stable beta- 
adrencrgic blockade (11). 
Atrial fibrillation model. The presence of atrial fibrillation 
was determined by the occurrence of a rapid (>400/min under 
control conditions), irregular atrial rhythm with varying dec- 
trogram confguration and cycle length. Atrial fibrillation 
induction was performed with a brief burst of rapid pacing at 
a cycle length of 100 ms and four times threshold current. The 
ability to maintain sustained atrial fibrillation was confirmed by 
the persistence of fibrillation for >30 min on at least two 
occasions. The six dogs that manifested sustained atrial fibril- 
lation in the absence of vagal stimulation were assigned to the 
atrial fibrillation group. In the 10 control dogs, atrial fibrilla- 
lion could be induced by atrial burst pacing but rarely lasted 
more than several seconds after induction, and it was never 
sustained >2 min. 
Activation mapping. An array of 112 bipolar electrodes 
with l-ram interpolar and 6-ram interelectrode istance, evenly 
spaced in five thin plastic sheets, was scwn to both atria to 
covcr the atrial epicardial surface (Fig. 1), as previously 
described (7,8). In addition to the recording sites, the sheets 
also contained six pairs of bipolar electrodes for regional 
stimulation. 
Each signal was filtered (30 to 400 Hz), digitized with 12-bit 
resolution and a l-kHz sampling rate and transmitted through 
duplex fiberoptic cables into a microcomputer (model 286, 
Compaq Computer). Software routines wcre used to amplify, 
display and analyze each electrogram as well as to generate 
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maps showing activation times at each electrode site (12). 
Interpolation techniques were used to produce isochrone maps 
of epicardial activation, but only measured activation times 
(not interpolated ata) were used for quantitative analysis. 
Each electrogram was analyzed by the use of computer- 
determined peak-amplitude criteria (13,14) and was reviewed 
manually to exclude low amplitude signals with indiscrete 
electrograms. The accuracy of measured activation times was 
-+0.5 ms. 
Experimental protocols. Activation data were acquired at 
the onset of atrial fibrillation, 5 min after the onset of drug 
administration and again at the time of atrial fibrillation 
termination. The acquisition system samples data continuously 
and stores them in a memory buffer, so that 8 s of data 
beginning up to 8 s before a manual trigger can be obtained. 
This allowed us to acquire activation data immediately before 
and at the time of atrial fibrillation termination. 
Atrial refractoriness and conduction properties were as- 
sessed under control conditions and then after flecainidc 
administration. Atrial effective refractory period was assessed 
by the extrastimulus technique, and atrial activation times wcrc 
determined by isochronal mapping. The direction of rapid 
propagation was determined from the isochrone maps, and a 
pair of bipolar electrode sites (1.6 to 2.0 cm apart) in the line 
of rapid propagation was used to measure local conduction 
velocity by dividing the distance between the sites by the 
interelectrode conduction time. The activation pattern was 
assessed for all activations to ensure that changes in conduc- 
tion time were not caused by changes in the direction of 
impulse propagation. The wavelength (minimal path length 
that can support reentry) was calculated as the product of 
conduction velocity and effective refractory period, as de- 
scribed by Wiener and Rosenblueth (15). 
Results were obtained uring stimulation at the right atrial 
appendage (Fig. 1, site 1) at basic cycle lengths of 400, 300, 25(I. 
200 and 150 ms. Two minutes was allowed at each basic cycle 
length before atrial effective refractory period and conduction 
velocity were measured. For effective refracto U period deter- 
mination, apremature stimulus (S:) was inserted after eve U 10 
basic ($1) stimuli, with the S~S e interval decreased by 10-ms 
decrements until failure to capture occurred. The longest S~S, 
interval that consistently failed to produce a propagated re- 
sponse was defined as the effective refractory period. 
To evaluate the possible role of regional variation in 
refractoriness and to assess whether the effects of flecainide 
were exerted in a spatially uniform fashion, we determined 
conduction velocity, atrial refractory period, and wavelength 
during stimulation at a cycle length of 250 ms at each of the 
seven stimulation sites shown in Figure 1. 
In dogs with sustained atrial fibrillation, control measure- 
ments were performed, and then atrial fibrillation was induced. 
After atrial fibrillation had persisted for 30 rain, flccainide was 
infused as a loading dose of 1 mg/kg over 15 min, lollowed by 
a maintenance infusion of 1.33 mg/kg per h. Plasma drug 
concentrations were measured with previously described high 
performance liquid chromatography methods (1~0. After the 
termination of atrial fibrillation, arrhythmia induction was 
attempted every 10 min. For control dogs, atrial effective 
refractory, period, conduction velocity and wavelength were 
determined at various basic cycle lengths and in various 
regions, as in dogs with atrial fibrillation. Bilateral vagal nerve 
stimulation was performed in control dogs with 0.l-s, 10-Hz 
stimuli at a voltage two-thirds the threshold for inducing 3 s of 
asystole to compare lectrophysiologic properties of dogs with 
sustained atrial fibrillation with those of control dogs under 
conditions (vagal stimulation) permitting the induction of 
sustained atrial fibrillation in control dogs. 
Data analysis. Group data are presented as mean value _+ 
SE. Comparisons between group mean values were made by 
two-way analysis of variance with the Scheffd test (17) or 
Student  test when only two groups of results were compared. 
Rate-dependent and regionally determined effects of flecain- 
ide on atrial effective refractou period, conduction velocity 
and wavelength were evaluated by analysis of variance with an 
F test for interaction (17). A two-tailed probability <5% 
defined statistical significance. 
The properties of atrial activation during atrial fibrillation 
were quantified in two ways. 1) The number of apparent atrial 
rcentrant circuits was determined as previously described (7) 
on the basis of the number of discrete zones in which adjacent 
electrodes were activated at the beginning and end of a local 
cycle, with reactivation of the early activation zone initiating 
local activity in the next cycle. 2) An index of inhomogeneity of 
activation was calculated. We reasoned that homogeneous 
activation should result in orderly successive activation of 
adjacent electrodes in the line of propagation of the atrial 
impulse. When activation becomes disorganized, activation 
times of adjacent sites become less coupled to one another, 
and the differences between activation times at adjacent sites 
should increase. We therefore calculated the absolute value of 
the difference in activation times at adjacent electrode pairs 
and determined the average value for activation time differ- 
cnces at all adjacent electrode pairs. The mean activation time 
difference was then divided by the cycle length to determine 
the fraction of the overall atrial fibrillation cycle occupied by 
activation time differences at adjacent electrodes. The latter 
wdue was termed the index of inhomogencity. An advantage of 
this index over an analysis of the number of reentrant circuits 
is that quantitative results are obtained without a need for an 
interpretation of patterns of reentry, which of necessity intro- 
duces a subjective lement. 
Resu l ts  
Electrophysiologic properties associated with ability to 
manifest sustained atrial fibrillation. There were no gross 
configurational bnormalities in dogs with atrial fibrillation-- 
they had no evidence of heart failure, atrial enlargement or 
other pathologic findings. There was no difference in size 
between dogs with atrial fibrillation (mean weight 22.2 _+ 
1.4 kg) and control dogs (mean weight 21.9 _+ 0.9 kg). Table 1 
compares the results obtained at a cycle length of 150 ms in 
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Table 1. Comparison of Electrophysiologic Variables in Dogs With Atrial Fibrillation Versus Control 
Dogs With and Without Vagal Stimulation (mean ~_ SE) 
CV* ERP* WL* HR Wenckebach CL 
/cmls) (ms) /cm) (beats/rain) (ms) 
Dogs with AF 90 -_ 4 80 +- 7 7.2 + 0.6 123 -~ 5 202 _+ 6 
Control dogs 
No VNS 92 + 5 95 +_ 3¢ 8.7 +_ 0.7f 121 +_ 2 198 _+ 3 
With VNS 108 ± 4 (~4 + 5f 6.9 * 0.5 74 _+ 3~ 422 _+ 12§ 
*Measured at basic cycle length of 150 ms. ~p < 0.05, :l:p < 0.01, §p < 0.001 versus corresponding value in dogs with 
atrial fibrillation (AF). CL = cycle length; CV = conduction velocity; ERP = effective refractory period; HR = 
spontaneous sinus rate; VNS = vagal nerve stimulation; WL = wavelength. 
dogs with atrial fibrillation to results in control dogs with and 
without vagal nerve stimulation. Atrial conduction velocity was 
not significantly different among the three groups of dogs. 
Atrial refractoriness and wavelength were significantly shorter 
in dogs with atrial fibrillation than in control dogs, and the 
wavelength in dogs with atrial fibrillation was not significantly 
different from that in control dogs subjected to vagal stimula- 
tion. Spontaneous sinus rate was substantially less and Wencke- 
bach cycle length considerably greater in control dogs during 
vagal nerve stimulation than in dogs with atrial fibrillation or 
control dogs under basal conditions. 
Figure 2 (A to C) shows the rate dependence of electro- 
physiologic properties in control dogs and dogs with atrial 
fibrillation. The overall pattern of rate dependence was similar 
in the two groups. However, atrial refractoriness decreased to 
a greater extent as pacing cycle length decreased in dogs with 
atrial fibrillation than in control dogs and was significantly ess 
in these animals at the shortest cycle length (150 ms) than in 
control dogs (Fig. 2A). Correspondingly, the wavelength for 
reentry showed greater abbreviation with rate in dogs with 
atrial fibrillation and was significantly shorter than that in 
control dogs at a basic cycle length of 150 ms. In addition to 
showing greater rate-dependent abbreviation, the effective 
refractory period in dogs with atrial fibrillation showed much 
greater regional variability (Fig. 3). Although conduction 
velocity showed less regional variability than effective refrac- 
tory period, conduction tended to be slower in regions of 
briefer refractoriness. As a result, there were large regional 
differences in the wavelength for reentry. The within-dog 
standard eviation of the effective refractory period was used 
as an index of regional variation in refractoriness. The stan- 
dard deviation of refractoriness averaged 19 _+ 3 ms in dogs 
with atrial fibrillation and 11 +_ 2 ms in control dogs (p < 0.01). 
The standard eviation of wavelength averaged 4.3 _+ 0.4 and 
2.6 _+ 0.3 cm in the same groups, respectively (p < 0.05). 
The increase in regional dispersion of refractoriness in dogs 
with atrial fibrillation appeared to result from shorter left atrial 
refractory periods (Fig. 1, sites 5 to 7). Figure 4 shows regional 
values of atrial effective refractory period from individual dogs 
with atrial fibrillation and control dogs for which we had 
complete data from at least six of the seven stimulation sites. 
Dogs with atrial fibrillation (right) had consistently shorter 
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Figure 2. A to C, Rate dependence of electrophysi- 
ologic properties in dogs with atrial fibrillation 
(AF) and control dogs and effects of flecainide 
(Flee.) on dogs with atrial fibrillation. Dependence 
of (A) atrial effective refractory period (ERP), (B) 
conduction velocity (CV) and (C) wavelength 
(WL) on basic cycle length (BCL). D, Percent 
change in effective refractory period, conduction 
velocity and wavelength caused by flecainide in 
dogs with atrial fibrillation as a function of basic 
cycle length. Statistically significant cycle length- 
dependent effects were noted for effective refrac- 
tory. period (p < 0.001) and conduction velocity 
(p < 0.01). *p < 0.05, **p < 0.01, ***p < 0.001 for 
value before and after flecainide in dogs with atrial 
fibrillation at each basic ycle length. +p < 0.05 for 
dogs with atrial fibrillation versus control dogs. 
Results are mean _+ SE. 
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Figure 3. Regional distribution of electrophysiologic properties in 
control dogs (diamonds), dogs with atrial fibrillation (open circles) and 
dogs with atrial fibrillation after flecainide (Flee.) (solid circles). Data 
were obtained during stimulation at a cycle length of 250 ms at each of 
the sites shown in Figure 1. Results are shown in panel A for effective 
refractory period (ERP), panel B for conduction velocity (CV) and 
panel C for wavelength (WE). 
refractory periods at left atrial sites (particularly sites 6 and 7 
[Fig. 1]) than the values in the rest of the atria. In contrast, 
effective refractory period values showed less regional varia- 
tion in control dogs (left). Overall, mean regional variation in 
effective refractory period was significantly greater in dogs with 
atrial fibrillation than in control dogs (p < 0.05). 
Activation during atrial fibrillation in control dogs and 
dogs with sustained atrial fibrillation. Bursts of rapid atrial 
pacing produced short runs of atrial fibrillation in control dogs. 
Atrial fibrillation induction was attempted 10 times in each 
control dog, and the mean duration for all control dogs was 
12.1 _+ 7.2 s. Activation mapping was used to relate the 
characteristics of atrial fibrillation to electrophysiologic prop- 
erties and the ability of atrial fibrillation to sustain itself. Figure 
5 (top) shows selected electrograms and activation data from a 
cycle of atrial fibrillation in a control dog and corresponding 
data from a dog with atrial fibrillation (bottom). In the control 
dog shown, atrial fibrillation lasted an average of 15 s (range 1 
to 50). Panel B shows the activation map (with 10-ms isochro- 
nal lines) corresponding to the cycle shown by the vertical lines 
in A. Panel A shows electrograms from nine electrode sites 
activated sequentially during one functional rcentrant circuit 
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Figure 4. Examples of regional variation in effective refractory period 
(ERP) as measured uring stimulation at a basic cycle length of 250 ms 
at each of the seven sites shown in Figure 1. Left, Results from six 
individual control dogs. Right, Results from six dogs with atrial 
fibrillation. Regional variation was significantly greater (p < 0.05, 
analysis of variance) among dogs with atrial fibrillation than among 
control dogs. 
during the cycle indicated. The locations of these electrodes 
are indicated by the letters A through 1 in panel B. Corre- 
sponding data from a dog with sustained atrial fibrillation are 
shown in panels C and D. Note that atrial activity is much more 
heterogeneous in the dogs with sustained atrial fibrillation. 
Many more isochrones are present, and there are a larger 
number of apparent reentrant circuits (arrows). 
These differences in activation pattern were seen consis- 
tently, as indicated by the quantitative analyses of activation 
pattern during atrial fibrillation shown in Figure 6. The num- 
ber of simultaneous reentrant circuits during atrial fibrillation 
in dogs with sustained atrial fibrillation averaged 6.3 + 0.4 and 
was significantly greater than that in control dogs (2.8 _+ 0.5, 
p < 0.01, vs. dogs with sustained atrial fibrillation). The index 
of inhomogeneity averaged 0.0090 _+ 0.0005 during sinus 
rhythm in dogs with sustained atrial fibrillation and increased 
282 WANG ET AL. JACC Vol. 26, No. 1 
FLECAIN1DE IN ATRIAl. FIBRILLATION July 1995:277-86 
A 
C 
A 
e 
C 
D 
E 
F 
G 
200 ms 
200 ms 
B 
A 
V. /t co . r .o ,  
DOG 
AVR AVR 
o 
L 
& 
AVR AVR 
Figure 5. Electrical activity during atrial fibrillation in a control dog 
(top, panels A and B) and a dog with atrial fibrillation (bottom, panels 
C and D). Recordings from selected electrode sites are shown in A and 
C, and the activation maps corresponding to the cycles defined by the 
vertical dashed lines in A and C are shown in B and D, respectively. 
Arrows in B and D correspond to functional reentrant circuits; lighter 
lines define consecutive 10-ms isochrones, and bolder lines indicate 
zones of functional conduction block. Numbers are the activation time 
range of given isochrones, and letters correspond to positions of 
electrodes whose recordings arc shown in A (for letters on activation 
map B) or C (for letters on map D). lsochrones were traced from 
computer-derived printouts. Abbreviations as in Figure 1. 
to 0.171 + 0.022 during atrial fibrillation (p < 0.01 vs. sinus 
rhythm). During atrial fibrillation in control dogs, the index of 
inhomogeneity averaged 0.050 _+ 0.016, a value significantly 
less (p < 0.01) than that in dogs with sustained atrial fibrilla- 
tion. These quantitative analyses indicate that atrial activation 
was substantially more heterogeneous in dogs with sustained 
atrial fibrillation than in control dogs and that the number of 
simultaneous reentrant circuits was considerably greater in 
dogs with sustained atrial fibrillation. 
Efficacy of flecainide in atrial fibrillation. Flecainide con- 
verted atrial fibrillation in all dogs with sustained atrial fibril- 
lation after a mean time of 10 rain (range 7 to 14) and at a 
mean concentration of 1.7 + 0.3 mg/liter, with termination of 
atrial fibrillation always occurring during the administration of 
the loading dose. After termination of atrial fibrillation, elec- 
trophysiologic variables were measured during the mainte- 
nance infusion, and then the maintenance infusion was 
stopped. Atrial fibrillation reinduction was attempted every 
l0 rain after the end of the maintenance infusion, and blood 
samples were obtained to correlate drug concentrations with 
the inducibility of atrial fibrillation. During the maintenance 
infusion, the arrhythmia could not be induced in any dog 
(mean concentration 1.4 +_ 0.3 rag/liter). After discontinuation 
of drug infusion, nonsustained atrial fibrillation became induc- 
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Figure 6. Index of inhomogenei b' (open bars, scale at left) during 
sinus rhythm in dogs with atrial fibrillation (Sinus), during atrial 
fibrillation i  control dogs, during atrial fibrillation i  dogs with atrial 
fibrillation and just before flecainide-induced t rmination (Term.) in 
dogs with atrial fibrillation. Mean (_-SE) number of functional reen- 
trant circuits during acycle of atrial fibrillation under each condition is 
shown by solid bars (scale at right). 
ible at a mean concentration f 0.6 ± 0.2 mg/liter. Sustained 
atrial fibrillation could eventually be maintained ata concen- 
tration of 0.3 ± 0.1 mg/liter. In three dogs, sustained atrial 
fibrillation began spontaneously during drug washout, but in 
the others it was induced by burst pacing. 
Effects of flecainide on activation during atrial fibrillation. 
Flecainide slowed atrial activation during atrial fibrillation. 
The mean cycle length of atrial fibrillation, determined as 
reported previously (7), was increased by the drug from 67 + 
7 to 123 ± 16 ms before atrial fibrillation termination (p < 
0.001). Flecainide increased the organization of atrial activa- 
tion and reduced the number of functional reentrant circuits 
(Fig. 6). The mean number of reentrant circuits was reduced to 
1.5 + 0.3 (p < 0.001) immediately before termination of the 
arrhythmia. The index of inhomogeneity was decreased by 
flecainide from 0.171 _+ 0.022 before the drug to (/.053 ± 0.010 
(p < 0.01) before termination. 
The changes in atrial activation associated with flecainide- 
induced atrial fibrillation termination are illustrated by results 
from one dog in Figure 7. Panel A shows electrograms from 
sites corresponding to positions A to J in panels B and C. 
Panels B and C show activation patterns during the last two 
cycles of atrial fibrillation during flecainide-induced rhythm 
reversion. Note that overall activation is more homogeneous 
than before flecainide (compare with results from the same 
dog in Fig. 5D). Activation during the penultimate cycle (panel 
B) is dominated by a single figure-of-eight macroreentrant 
circuit. Reactivation from sites I and J to the region of sites A 
to C initiates the final cycle (panel C). The cycle shown in C 
terminates because of block in the cross-hatched zone in the 
lower right atrium adjacent to the atrioventricular ring (AV) 
(note the lack of activation at site J during the last cycle in 
panel A). In all cases, the termination of atrial fibrillation by 
flecainide was associated with an increase in the homogeneity 
of atrial activation and a reduced number of rcentrant circuits, 
with activation in the final circuits terminating either by block 
(as in Fig. 7) or by collision of wavefronts as previously shown 
(8). 
Effects of flecainide on electrophysiologic determinants of 
reentry. The rate-dependent effects of flecainide on atrial 
effective refractory period, conduction velocity and the mini- 
mal wavelength for reentry are shown in Figure 2. Flecainide 
produced rate-dependent reductions in atrial conduction ve- 
locity (panel B) and increases in atrial effective refractory 
period (panel A). Drug-induced changes in refractoriness 
exceeded those in conduction velocity, causing important 
increases in wavelength (panel C). Drug-induced changes in 
wavelength increased with decreasing cycle length (panel D), 
and at the shortest cycle length (150 ms) the wavelength in the 
presence of flecainide qualed the value in control dogs. 
Regional effects of flecainide on conduction and refractori- 
ness. Flecainide increased the effective refractory period and 
slowed conduction i all regions of the atria (Fig. 3). Flecainide 
increased refractoriness the most in zones that had the shortest 
refractoriness before the drug. Consequently, atrial refractori- 
ness showed much less regional variation after flecainide (Fig. 
3A), with the standard eviation of effective refractory period 
decreasing from 17 _+ 1 to 8 z 2 ms (p < 0.01). As a result of 
the homogenization in regional refractoriness, the wavelength 
became less variable, and regional wavelengths after the drug 
were similar to control values (Fig. 3C). 
Discuss ion  
We showed that in a subset of dogs the atria can support 
sustained atrial fibrillation despite bilateral vagotomy and 
beta-adrenoceptor blockade. The underlying electrophysi- 
ologic substrate includes reduced refractoriness and wave- 
length at rapid rates and a greater dispersion in atrial refrac- 
toriness. These result in increased heterogeneity of activation 
during atrial fibrillation, associated with a larger number of 
simultaneous functional reentrant circuits. Flecainide termi- 
nated atrial fibrillation by causing a tachycardia-dependent 
increase in atrial effective refractory period, reducing the 
number of reentrant circuits and the heterogeneity of atrial 
activation. 
Factors associated with ability to manifest sustained atrial 
fibrillation. The importance of the reentrant path length in 
the physiology of atrial fibrillation was first discussed by Lewis 
et al. (18), who agreed with Rothberger and Winterberg (19) 
that short refractory periods were important to the ability to 
produce atrial fibrillation. Rensma et al. (1) showed that the 
wavelength was a critical determinant of reentrant atrial 
arrhythmias. A subsequent study from the same group re- 
ported a duration of atrial fibrillation in conscious (autonom- 
ically intact) dogs between 4s and 66 rain, with a mean of 211 s 
(2). 
Vagal stimulation results in the ability to sustain atrial 
fibrillation as long as vagal stimulation continues and is 
associated with a reduced wavelength for reentry and an 
increased regional dispersion in atrial refractoriness (7,20-22). 
In the present experiments, we studied dogs that had the 
unusual property of supporting sustained atrial fibrillation in 
the absence of vagal nerve input. Two electrophysiologic 
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Figure 7. Selected elcctrograms (A) at time of atrial fibrillation 
termination by flecainide in the samc dog whose activation during 
atrial fibrillation beforc flecainide is shown in Figure 5D. B and C, 
Activation during the last two cycles of atrial fibrillation, correspond- 
ing to intervals delineated by dashed vertical ines in A. Locations of 
electrode sites at which the recordings shown in A were obtained are 
indicated by corresponding letters in B and C. Reentry.' followed a 
figure-of-eight pattern in the cycle shown in B. During the last cycle 
(C), reentry is terminated by block in the hatched area. Isochrones 
were traced from computer-derived printouts. V - ventricular clec- 
trograms recorded by atrial electrodes (A); other abbreviations a in 
Figure 1. 
characteristics of these dogs may have contributed to their 
ability to sustain atrial fibrillation: 1) These dogs manifested 
greater rate-dependent effective refractory period abbrevia- 
tion. Consequently, they had small wavelengths for reentry at 
short basic cycle lengths, with a wavelength at a cycle length of 
150 ms that was substantially smaller than that in control dogs 
(Fig. 2C) and in the same range as the wavelength of control 
dogs during vagal stimulation (Table 1), Activation mapping 
showed that during fibrillation, multiple small zones of atrial 
reentry coexisted in sustained atrial fibrillation dogs (Fig. 5), 
which requires a short wavelength according to the leading 
circle hypothesis (23). Multiple small circuits are essential for 
the maintenance of atrial fibrillation, as first proposed in 
Gordon Moe's "multiple wavelet" hypothesis (24,25) and 
subsequently demonstrated byAllessie et al. (26). 
2) Increased ispersion of atrial refractoriness may have 
contributed to sustained fibrillation (Fig. 3 and 4). Variability 
in regional refractoriness may have contributed to the greater 
heterogeneity of activation during atrial fibrillation in dogs 
with atrial fibrillation, which increases the likelihood that 
recently excited tissue will be located near tissue recovering 
excitability and thus available for reactivation. Lammers et al. 
(27,28) have shown that inhomogeneities in conduction are 
important in the initiation of atrial reentry, in isolated rabbit 
atria. 
The mechanisms accounting for enhanced rate-dependent 
atrial refractory period abbreviation and dispersion in refrac- 
toriness in dogs with atrial fibrillation are unclear. Dogs with 
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atrial fibrillation showed more rate-dependent refractoriness 
abbreviation and regional variation than control dogs, but both 
groups showed the same basic qualitative properties. Thus, 
dogs with atrial fibrillation may present he extreme of a 
continuum of normal atrial refractory properties. 
Mechanism of flecainide action in atrial fibrillation. Fle- 
cainide has been shown to be effective in the conversion of 
atrial fibrillation to sinus rhythm (29-32), in the maintenance 
of sinus rhythm after cardioversion (33,34) and in the preven- 
tion of atrial fibrillation paroxysms (35,36). The efficacy of class 
Ic drugs in atrial fibrillation appears paradoxic because this 
class of agents is considered to slow conduction without 
altering refractoriness (37), changes that would be expected to 
decrease the wavelength and increase the likelihood of reentry 
(1,23). We previously showed that flecainide reduces rate- 
dependent a rial action potential duration and refractoriness 
abbreviation, causing tachycardia-dependent increases in atrial 
refractory period (10,16). The present study shows that flecain- 
ide terminates sustained atrial fibrillation in the absence of 
cardiac vagal input by mechanisms similar to those previously 
described in the vagotonic model (7). 
The potential ionic mechanism of the actions of flecainide 
on atrial tissue are incompletely understood. The drug inhibits 
the delayed rectifier (38) and the transient outward current 
(39), both of which can play a role in atrial repolarization 
(40,41). The rate dependence of drug action on atrial repolar- 
ization in dog atrium appears to result from sodium channel 
blockade, which reduces tachycardia-dependent c llular so- 
dium loading and sodium/potassium-adenosine tr phosphatase 
stimulation (39). Rate-dependent sodium channel block could 
also prolong refractoriness independently of changes in repo- 
larization by depressing atrial excitability. 
Novel aspects and potential significance of our observa- 
tions. To our knowledge, the present study is the first to 
show that sustained atrial fibrillation can be induced repro- 
ducibly in the absence of vagal tone and beta-adrenoeeptor 
stimulation i a subset of dogs and to study the electrophysi- 
ologic properties that account for their ability to sustain 
atrial fibrillation. In addition, we believe that this study is 
the first to evaluate the eleetrophysiologic mechanisms by 
which flecainide alters atrial activation to terminate atrial 
fibrillation in a model acking enhanced vagal tone. Because 
the latter is unusual in patients with atrial fibrillation, these 
results are relevant o understanding the drug's ability to 
terminate atrial fibrillation in humans. 
The mechanisms of idiopathic or "lone" atrial fibrillation 
in humans are uncertain. The majority of patients present 
with paroxysmal atrial fibrillation (42), and patients with 
drug-resistant a rial fibrillation may have a variety of focal 
histopathologic findings despite the absence of clinically 
detected cardiac disease (43). Patients with lone atrial 
fibrillation have a shorter atrial refractory period (44,45) 
and a greater dispersion of atrial refractoriness (45) than 
normal subjects. The ability to sustain atrial fibrillation in 
humans is associated with evidence of a reduced wavelength 
(46). Our atrial fibrillation group of dogs had a number of 
features in common with patients with lone atrial fibrilla- 
tion. They had shorter refractory periods at rapid rates, 
smaller wavelengths and greater regional dispersion i  atrial 
refractoriness than control dogs. The mechanisms permit- 
ting atrial fibrillation to be sustained in these animals may 
thus give insights into the mechanisms of idiopathic atrial 
fibrillation in humans. Dogs with atrial fibrillation showed a 
similar pattern but greater magnitude of rate-dependent 
refractoriness abbreviation and variability than control 
dogs. This finding raises the intriguing possibility that, at 
least in some patients, idiopathic atrial fibrillation may 
occur when atrial electrophysiologic properties are at one 
end of the spectrum of normal, with combinations of 
regional refractoriness and conduction velocity that allow 
atrial fibrillation to be sustained. By contrast, in at least one 
study (47), patients predisposed to reentrant atrial arrhyth- 
mias showed attenuated rate-dependent changes in atrial 
refractory period. 
Limitations of the model. Although the vagus nerves were 
transeeted in all our dogs, vagal nerve endings could have 
released acetylcholine and contributed to the electrophysi- 
ologic properties of dogs with atrial fibrillation. Two pieces of 
evidence weigh against his possibility. First, although dogs 
with atrial fibrillation had shorter atrial refractory period and 
wavelength values than control dogs, their sinus rate and 
Wenckebach cycle length were similar to those of control dogs 
without vagal stimulation (Table 1); that is, there was no 
evidence of enhanced cholinergic action on the sinus and AV 
nodes. Second, vagal activation results in the shortest effective 
refractory period values in the right atrium and longest in the 
left atrium (7,20-22). In dogs with atrial fibrillation (Figs. 3 
and 4), refractory periods were shortest in the left atrium (sites 
6 and 7 [Fig. 1]) and longest in the right atrium (sites 2, 3 and 
4 [Fig. 1]). 
The ability to manifest sustained atrial fibrillation is 
unusual in normal dogs, as is the inducibility of sustained 
atrial fibrillation in patients without organic heart disease. 
We were therefore limited to a small study group of dogs 
with atrial fibrillation. Although there was no gross cardiac 
pathologic findings in these animals, the possibility of focal, 
microscopic heart disease, as noted in patients with idio- 
pathic atrial fibrillation (43), cannot be excluded because 
microscopic examination of cardiac tissue was not per- 
formed. 
It would have been interesting to calculate the wavelength 
by directly measuring the effective refractory period and 
conduction velocity during atrial fibrillation. Unfortunately, 
neither can be measured precisely during atrial fibrillation 
because of the nature of the arrhythmia. We assume that the 
wavelength at a short pacing cycle length (150 ms) is closely 
related to the wavelength during atrial fibrillation. 
We thank Emma De Blasio and Christine Villemaire for technical assistance, 
Ma~' Morello for typing the manuscript. 
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